Theravance Biopharma Inc (NASDAQ:TBPH) Short Interest Update

Theravance Biopharma Inc (NASDAQ:TBPH) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totalling 5,202,500 shares, a decline of 7.5% from the June 30th total of 5,626,300 shares. Based on an average daily volume of 303,500 shares, the short-interest ratio is currently 17.1 days. Currently, 12.4% of the company’s stock are sold short.

A number of brokerages have commented on TBPH. Piper Jaffray Companies set a $55.00 price objective on Theravance Biopharma and gave the stock a “buy” rating in a report on Wednesday, July 31st. BidaskClub raised Theravance Biopharma from a “hold” rating to a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Theravance Biopharma has an average rating of “Buy” and a consensus target price of $44.25.

TBPH traded down $0.02 during midday trading on Thursday, reaching $21.27. 217,962 shares of the company were exchanged, compared to its average volume of 252,225. The company’s fifty day moving average price is $18.58 and its 200 day moving average price is $21.23. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -5.33 and a beta of 1.75. Theravance Biopharma has a one year low of $15.18 and a one year high of $35.48.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.50. The company had revenue of $26.15 million during the quarter, compared to analyst estimates of $13.92 million. Theravance Biopharma had a negative return on equity of 2,631.15% and a negative net margin of 369.67%. On average, sell-side analysts forecast that Theravance Biopharma will post -4.28 EPS for the current year.

In other Theravance Biopharma news, Director Donal O’connor sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $20.46, for a total transaction of $81,840.00. Following the completion of the sale, the director now directly owns 30,244 shares of the company’s stock, valued at approximately $618,792.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.60% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Theravance Biopharma in the first quarter valued at approximately $156,000. CWM Advisors LLC purchased a new position in Theravance Biopharma in the second quarter valued at approximately $167,000. BNP Paribas Arbitrage SA lifted its stake in Theravance Biopharma by 882.7% in the first quarter. BNP Paribas Arbitrage SA now owns 9,965 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 8,951 shares during the last quarter. Nisa Investment Advisors LLC purchased a new position in Theravance Biopharma in the first quarter valued at approximately $254,000. Finally, DekaBank Deutsche Girozentrale lifted its stake in Theravance Biopharma by 64.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock valued at $306,000 after purchasing an additional 7,500 shares during the last quarter. 83.83% of the stock is owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

See Also: What is a Futures Contract?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit